Pharmacokinetic and pharmacodynamic aspects of gastroretentive dosage forms.

Controlled release gastroretentive dosage forms (CR-GRDF) enable prolonged and continuous input of the drug to the upper parts of the gastrointestinal (GI) tract and improve the bioavailability of medications that are characterized by a narrow absorption window. CR-GRDF provide a means to utilize all the pharmacokinetic (PK) and pharmacodynamic (PD) advantages of controlled release dosage forms for such drugs. Thus, CR-GRDF may improve therapy with clinically used medications, as well as enable oral administration of drugs, or drug candidates, that hitherto had to be infused parenterally. This manuscript discusses the complexity of the PK and PD factors that influence the treatment benefits of CR-GRDF and summarizes the results of our recent in vivo investigations in animal models (rats and dogs) and in human subjects. We found that a CR-GRDF formulation was superior to the other modes of administration for levodopa and riboflavin, but not for metformin. The PK and PD rationales of GRDFs for the studied drugs are presented and discussed. We conclude that due to the complexity of the PK and PD factors for a certain drug, the rationale for continuous administration obtained by CR-GRDF should be assessed and established in vivo.

[1]  W. Stigelman,et al.  Goodman and Gilman's the Pharmacological Basis of Therapeutics , 1986 .

[2]  A. Hoffman,et al.  Pharmacodynamic aspects of sustained release preparations. , 1998, Advanced drug delivery reviews.

[3]  W. Erni,et al.  The hydrodynamically balanced system: a novel principle of controlled drug release. , 1987, European neurology.

[4]  C. Rhodes,et al.  Controlled-Release Drug Delivery Systems for Prolonged Gastric Residence: An Overview , 1996 .

[5]  G. Levy.  PHARMACOKINETIC APPROACHES TO THE STUDY OF DRUG INTERACTIONS * , 1976, Annals of the New York Academy of Sciences.

[6]  A. Hoffman,et al.  Pharmacokinetic-pharmacodynamic analysis of the glucose-lowering effect of metformin in diabetic rats reveals first-pass pharmacodynamic effect. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[7]  A. Hoffman,et al.  Pharmacodynamic aspects of modes of drug administration for optimization of drug therapy. , 1999, Critical reviews in therapeutic drug carrier systems.

[8]  H. Kanerva,et al.  Site dependent bioavailability and metabolism of levosimendan in dogs. , 1999, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[9]  R. Roos,et al.  International (NL-UK) double-blind study of Sinemet CR and standard Sinemet (25/100) in 170 patients with fluctuating Parkinson's disease , 1996, Journal of Neurology.

[10]  J. Nutt,et al.  Duodenal and gastric delivery of levodopa in parkinsonism , 1988, Annals of neurology.

[11]  M. da Prada,et al.  Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. , 1987, European neurology.

[12]  S. Rietbrock,et al.  Concentration-Effect Relationship of Levodopa in Patients with Parkinson’s Disease , 1995, Clinical pharmacokinetics.

[13]  S. Christensen.  The biological fate of riboflavin in mammals. A survey of literature and own investigations. , 2009, Acta pharmacologica et toxicologica.

[14]  Sara Eyal,et al.  Novel levodopa gastroretentive dosage form: in-vivo evaluation in dogs. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[15]  Y. Michotte,et al.  Clinical and pharmacokinetic comparison of oral and duodenal delivery of levodopa/carbidopa in patients with Parkinson's disease with a fluctuating response to levodopa , 2004, European Journal of Clinical Pharmacology.

[16]  S. Chaussade,et al.  Metformin in the digestive tract. , 1988, Diabetes research and clinical practice.

[17]  I. Wilding,et al.  Effect of altered gastric emptying and gastrointestinal motility on metformin absorption. , 2000, British journal of clinical pharmacology.

[18]  W. Jusko,et al.  Absorption, Protein Binding, and Elimination of Riboflavin , 1975 .

[19]  Kinam Park,et al.  Gastric retentive drug-delivery systems. , 1998, Critical reviews in therapeutic drug carrier systems.

[20]  L. Hansson,et al.  Long‐term intraduodenal infusion of a water based levodopa‐carbidopa dispersion in very advanced Parkinson's disease , 1998, Acta neurologica Scandinavica.

[21]  P. Marchetti,et al.  Plasma biguanide levels are correlated with metabolic effects in diabetic patients , 1987, Clinical pharmacology and therapeutics.

[22]  I. Robertson,et al.  GASTRIC EMPTYING OF SOLID RADIOPAQUE MARKERS IN HEALTHY DOGS , 1996 .

[23]  I. Alferiev,et al.  A peptide prodrug approach for improving bisphosphonate oral absorption. , 2000, Journal of medicinal chemistry.

[24]  L. Goodman,et al.  The Pharmacological Basis of Therapeutics , 1941 .

[25]  G. Levy,et al.  Pharmacokinetics of Metformin Gastric‐Retentive Tablets in Healthy Volunteers , 2001, Journal of clinical pharmacology.

[26]  A. Hoffman,et al.  Novel Gastroretentive Dosage Forms: Evaluation of Gastroretentivity and Its Effect on Riboflavin Absorption in Dogs , 2002, Pharmaceutical Research.

[27]  A. Hoffman,et al.  Preclinical evaluation of pharmacokinetic-pharmacodynamic rationale for oral CR metformin formulation. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[28]  Roger L. Black,et al.  Goodman and Gilman's The Pharmacological Basis of Therapeutics , 1991 .